Priapism associated with concurrent use of phosphodiesterase inhibitor drugs and intracavernous injection therapy.
McMahon
C G
CG
Australian Centre for Sexual Health, Sydney, Australia. cmcmahon@mail.usyd.edu.au
D000328:Adult; D000527:Alprostadil / Q000009:adverse effects; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000009:adverse effects; D010646:Phentolamine / Q000009:adverse effects; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects*; D010879:Piperazines / Q000009:adverse effects*; D011317:Priapism / Q000139:chemically induced*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D014665:Vasodilator Agents / Q000009:adverse effects
D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D010208:Papaverine; D000527:Alprostadil; D010646:Phentolamine